+1,621.9%
ASTS vs MRNA
+30.4%
+1,591.5%
-68.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.1% | -3.6% | +9.7% | +6.5% |
| 7D | +18.5% | -9.0% | +27.5% | +19.5% |
| 30D | -8.1% | +137.2% | -145.3% | -24.8% |
| 3M | -28.2% | +194.8% | -223.0% | -45.6% |
| 6M | -26.1% | +167.2% | -193.3% | -42.2% |
| YTD | -9.0% | +375.9% | -384.8% | -41.9% |
| 1Y | +62.2% | +465.2% | -403.0% | -1.8% |
| 3Y | +1,621.9% | +30.4% | +1,591.5% | +1,251.0% |
| All | +1,621.9% | +30.4% | +1,591.5% | +1,251.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling